Ligand buys a handful of biologics for $4M; Merck KGaA and Threshold get on the FDA fast track;

@FierceBiotech: Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma. News | Follow @FierceBiotech

@JohnCFierce: It's a great time to go shopping in Europe. Three deals in the last 24 hours, with U.S. biotechs buying into European companies. | Follow @JohnCFierce

> Merck KGaA and Threshold Pharmaceuticals ($THLD) picked up the FDA's fast-track designation for evofosfamide, in Phase III development for pancreatic cancer. More

> Ligand Pharmaceuticals ($LGND) acquired more than 15 biologics programs from Selexis for $4 million in cash, picking up assets in various stages of development. News

> Gene therapy biotech Juventas Therapeutics raised $13.5 million in equity, cash that will support the development of its lead asset as a treatment for organ injury. Item

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA approves Nevro device that eliminates side effect of spinal stimulation. Article | Follow @VarunSaxena2

@EmilyWFierce: Google signs on Harvard doc to lead bioinformatics study. News | Follow @EmilyWFierce

> Autonomic raises $38M to fund U.S. pivotal trial, EU marketing for headache microstimulator. News

> FDA grants priority review status in first-line glioblastoma for Medtronic, J&J-backed startup Novocure. More

Pharma News

@FiercePharma: Teva passed up an opportunity to buy Mylan target Perrigo: Globes. Report | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

> Analysts 'skeptical' Sanofi can turn around Afrezza launch, but DTC ads are coming. News

> Biogen's hot MS meds could push Pfizer off its CNS throne. Article

> GSK chief sees cheap money spurring 'poor choices' in pharma M&A. More

Pharma Manufacturing News

> 33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme. Report

> Alexion to build $506M plant in Ireland, add 200 workers. News

> Hikma building its sterile injectable operation with Bedford equipment and products. Story

> Eisai to boost Indian API production to cut costs. Item

> Novartis' Sandoz expands Poland plant with packaging facility. Article

Pharma Asia News

> Australia negotiates pharmacy reimbursement increase as part of budget savings. Report

> Japan's Oncolys begins PhI trial of cancer drug licensed from Astellas. Item

> India eyes new manufacturing, clinical trial models to sell generics to Japan. More

> India's Punjab state goes its own way on drug price caps. Story

> Takeda, Orexigen end CV study for obesity drug Contrave. Article

Drug Delivery News

> Researchers turn to bacteria secretion systems to deliver proteins. Report

> Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. More

> Supercooled nanoparticles offer targeted delivery approach. Story

> Gene editing player gets $25M in Series A round. Item

> Neuroderm stock up as FDA lifts hold on its subcutaneously delivered Parkinson's candidate. Article

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.